Trapeziometacarpal Arthritis Injection: The Eaton-Stage Decision Framework That Maps Every Biologic to Your CMC Grade
Trapeziometacarpal Arthritis Injection: The Eaton-Stage Decision Framework That Maps Every Biologic to Your CMC Grade
Introduction: Why Injection Outcomes May Depend on a Stage Many Patients Have Never Heard Of
Trapeziometacarpal arthritis injection decisions rarely follow a systematic framework—yet they should. Thumb base arthritis, also known as CMC joint osteoarthritis or rhizarthrosis, ranks as the second most common degenerative joint disease of the hand. The condition affects approximately 15% of women and 7% of men overall, with prevalence climbing to 17–33% among postmenopausal women.
The core problem facing most patients is straightforward: they receive a corticosteroid injection without any discussion of disease stage, injection type rationale, or the expanding menu of regenerative alternatives. The physician administers the injection, the patient hopes for relief, and neither party addresses whether that particular intervention was the optimal choice for that particular joint.
The Eaton-Littler classification system offers a solution. This four-stage radiographic framework has guided hand surgeons worldwide for decades, yet it rarely enters patient conversations about injection selection. Understanding one’s Eaton stage transforms the injection decision from guesswork into strategy.
This article provides a stage-by-stage injection decision map covering corticosteroids, hyaluronic acid, PRP (including the critical single-dose versus multi-dose distinction that explains why patient experiences vary so dramatically), prolotherapy, bone marrow aspirate concentrate (BMAC), and the clinical indicators that shift the conversation toward surgery.
Neither EULAR nor the American College of Rheumatology currently provides strong guideline endorsements for intra-articular injections in TMC osteoarthritis. This guideline gap makes a structured, evidence-based framework not merely helpful but essential.
Understanding the CMC Joint: Why the Thumb Base Is Uniquely Vulnerable
The trapeziometacarpal joint—the articulation between the trapezium bone at the wrist base and the first metacarpal bone of the thumb—features a distinctive saddle-shaped anatomy. This configuration enables the thumb’s remarkable range of motion: opposition, circumduction, and the precise pinching movements that distinguish human hand function.
However, this mobility comes at a biomechanical cost. The CMC joint experiences forces up to 12–13 times the applied pinch force. A seemingly gentle pinch generates enormous stress at the joint surface, explaining why everyday tasks such as opening jars, turning keys, or writing become painful as cartilage erodes.
Population data from the Rotterdam Study reveals that radiographic CMC-1 osteoarthritis prevalence reaches approximately 25.3% in adults aged 55 and older. Females face nearly twice the risk of males (adjusted odds ratio of 1.98). Among individuals over 80, radiographic prevalence climbs to 91%.
Patients encounter various terms for this condition—CMC arthritis, thumb base arthritis, basal thumb arthritis, and rhizarthrosis all describe the same degenerative process. Recognizing this terminology overlap helps patients connect their specific diagnosis to available treatment information.
Critically, radiographic prevalence does not equal surgical inevitability. Most individuals adapt to thumb base arthritis without requiring surgery, which underscores why effective non-surgical treatment for osteoarthritis matters enormously.
The Eaton-Littler Classification: The Staging System That Should Drive Every Injection Decision
The Eaton-Littler system (Stages I–IV) represents the standard radiographic staging framework for TMC osteoarthritis. Hand surgeons worldwide use this classification to guide treatment planning and establish prognosis.
An important nuance warrants attention: Eaton staging does not reliably correlate with symptom severity. A patient with Stage II radiographic findings may experience more pain and functional limitation than a Stage III patient. This disconnect means clinical assessment must accompany imaging—staging informs but does not dictate the treatment conversation.
Stage I: Early Joint Changes
Stage I presents as normal or slightly widened joint space with possible synovial hypertrophy but no significant bony changes. This stage often appears in younger patients or those with early-onset disease.
Stage I represents the ideal window for regenerative intervention. Cartilage remains largely intact, providing a structural scaffold for regenerative therapies. Treatment at this stage aims at both symptom relief and potential disease modification.
Appropriate injection options at Stage I include PRP (particularly multi-injection protocols), hyaluronic acid viscosupplementation, and prolotherapy. Corticosteroids may address acute flare management but are not the preferred long-term strategy given cartilage preservation goals.
Stage II: Mild Arthritic Changes
Stage II demonstrates joint space narrowing, subchondral sclerosis, osteophyte formation less than 2 mm, and possible loose bodies—moderate structural changes that confirm established arthritis.
This stage represents the most common presentation among patients seeking injection-based care and offers the broadest range of appropriate injection options. All major injection modalities—corticosteroids, hyaluronic acid, PRP, prolotherapy, and BMAC—merit consideration at Stage II. Selection depends on patient goals, prior treatment history, and provider expertise.
Ultrasound or fluoroscopic guidance becomes strongly recommended at this stage due to the small size of the TMC joint. Injection accuracy significantly impacts outcomes.
Stage III: Moderate-to-Severe Arthritic Changes
Stage III shows significant joint space narrowing or obliteration, osteophytes greater than 2 mm, subchondral cysts, and sclerosis—but the trapezium itself remains intact.
Regenerative injection options become more limited at Stage III but remain viable, particularly for patients who are not surgical candidates or who wish to delay surgery. Corticosteroids and hyaluronic acid remain appropriate for symptom management. PRP and BMAC may still offer benefit, though with more modest expectations.
The surgical consultation threshold emerges at Stage III. Patients who fail multiple injection modalities should have a conversation about surgical options, though non-surgical management can still be pursued. Data indicate that 22–33% of patients convert from nonsurgical to surgical management, with most conversions occurring within the first year.
Stage IV: Advanced Disease — When Injection Therapy Steps Aside
Stage IV involves pantrapezial arthritis affecting the scaphotrapezoid or trapezoid-second metacarpal joints in addition to the CMC-1 joint—the most advanced radiographic stage.
The clinical decision point is clear: Stage IV disease typically warrants surgical consultation rather than continued injection-based management as the primary strategy. Surgical options include trapeziectomy and total joint arthroplasty. A 2026 five-year randomized controlled trial found that total joint arthroplasty did not demonstrate superior patient-reported outcomes compared to trapeziectomy, with five-year survival of 73% for trapeziectomy and 93% for arthroplasty.
Injections may still play a palliative role in Stage IV patients who are poor surgical candidates or who decline surgery, but expectations must be calibrated accordingly.
Corticosteroid Injections: The Default Option — What the Evidence Actually Shows
Corticosteroids became the default injection for CMC arthritis due to rapid onset, low cost, wide availability, and effective short-term pain relief lasting one to six weeks.
The diminishing returns problem warrants acknowledgment: repeated corticosteroid injections show declining efficacy over time and raise concerns about potential cartilage damage with high-dose repeated use.
Neither EULAR nor ACR formally recommends corticosteroids specifically for TMC osteoarthritis, yet they remain the most commonly used first-line treatment—a disconnect worth understanding.
Best use cases include acute pain flares, patients needing rapid relief before a specific event, or as a diagnostic tool to confirm an intra-articular pain source. Corticosteroids are appropriate across all Eaton stages for symptom management but are not the preferred long-term strategy for Stages I–II where cartilage preservation remains a goal.
Hyaluronic Acid (Viscosupplementation): The Slow-Burn Option With Durable Relief
Hyaluronic acid injections restore synovial fluid viscosity, reduce friction, and may provide anti-inflammatory and chondroprotective effects.
Randomized controlled trials have demonstrated that 88% of patients report improvement at 26 weeks with hyaluronic acid, with relief extending beyond six months—a durability advantage over corticosteroids. The trade-offs include slower onset than corticosteroids and higher cost.
The 2024 systematic review finding that hyaluronic acid and corticosteroids show comparable outcomes at six months positions hyaluronic acid as a legitimate alternative rather than a second-tier option.
Hyaluronic acid is appropriate for Eaton Stages I–III and may be particularly valuable for patients experiencing diminishing returns from corticosteroids. Imaging guidance remains essential for accurate intra-articular delivery in the small TMC joint.
PRP Injections for Thumb CMC Arthritis: The Single-Dose vs. Multi-Dose Distinction That Changes Everything
Platelet-rich plasma, derived from the patient’s own blood and concentrated to deliver growth factors, may stimulate tissue repair and reduce inflammation. Yet patient experiences with PRP for thumb arthritis vary dramatically—and the answer lies in protocol differences.
A 2025 double-blind randomized controlled trial from Stockholm (n=90) found that a single PRP injection did not show statistically significant superiority over saline placebo for pain on load at six months. This Level 1 evidence demands acknowledgment.
The clinical takeaway is clear: the evidence does not indict PRP as ineffective—it indicts single-injection protocols as insufficient. Multi-injection PRP protocols show meaningfully better outcomes at 12 months.
PRP concentration and preparation variability further explain outcome differences across studies. The therapy is appropriate for Eaton Stages I–III, with the strongest rationale for Stages I–II where tissue retains regenerative capacity.
Prolotherapy: The Evidence-Backed Option Almost No One Is Discussing
Prolotherapy involves intra-articular injection of a proliferant solution—typically hypertonic dextrose—intended to stimulate a controlled healing response and strengthen periarticular structures.
Despite meaningful randomized controlled trial evidence, prolotherapy rarely enters discussions about CMC arthritis treatment. A double-blind RCT found methylprednisolone was more effective short-term, but at six months, dextrose prolotherapy showed a “remarkable difference” in favor over corticosteroids—a reversal of the short-term advantage.
The safety profile is notable: no severe side effects were reported in the prolotherapy arm. The proposed mechanism suggests dextrose prolotherapy may stimulate collagen synthesis and ligamentous tightening around the CMC joint, addressing joint laxity—a contributing factor to TMC osteoarthritis progression.
Prolotherapy is appropriate for Eaton Stages I–III and may be particularly relevant for early-stage patients with joint laxity as a contributing factor.
BMAC and Emerging Regenerative Injectables: The Frontier of CMC Joint Preservation
Bone marrow aspirate concentrate represents a concentration of cells derived from the patient’s own bone marrow, containing mesenchymal stem cells, growth factors, and anti-inflammatory cytokines.
A University of Bordeaux study (2021, n=27 arthritic thumbs) was described as the first published study on intra-articular BMAC injection for thumb CMC osteoarthritis, with encouraging results and the conclusion that injections “appear to be an effective means of postponing surgery.”
BMAC for CMC osteoarthritis remains early-stage evidence—promising but not yet supported by large randomized controlled trials. Patients should understand this distinction.
Autologous fat grafting (lipofilling) represents another emerging regenerative option showing early promise, though similarly limited by small study sizes. ChondroFiller Liquid, a cell-free collagen scaffold, is being investigated in an active 2025 clinical trial as an intra-articular injection for TMC osteoarthritis, representing the next wave of non-cellular regenerative approaches.
As of 2026, the FDA has not approved stem cell or BMAC products specifically for orthopedic conditions, but treatments can be administered within FDA regulatory frameworks by qualified providers. BMAC is appropriate for Eaton Stages I–III, with the strongest rationale for Stages II–III where structural changes are present but surgical intervention is not yet indicated.
The Role of Imaging Guidance: Why Injection Accuracy Is Non-Negotiable for the CMC Joint
The TMC joint is small, irregularly shaped, and surrounded by tendons and neurovascular structures—making blind injection technically difficult.
The EUROVISCO 2020 group strongly recommends ultrasound or fluoroscopic guidance for both diagnostic and therapeutic injections of the TMC joint. Unguided injections may miss the joint space entirely, delivering the therapeutic agent into periarticular soft tissue rather than the joint—a key reason why some patients report no benefit from injections.
Ultrasound offers real-time visualization without radiation and allows dynamic assessment. Fluoroscopy provides excellent bony landmark visualization and can confirm intra-articular placement with contrast.
Patients should ask whether their provider uses imaging guidance and which modality, as this represents a meaningful factor in expected outcomes. Unicorn Bioscience administers all injections using advanced imaging guidance, including ultrasound-guided injection and X-ray technology, to ensure accurate delivery to the targeted treatment area.
Comparing Options: A Quick-Reference Guide by Eaton Stage
Stage I: PRP (multi-injection), hyaluronic acid, prolotherapy—focus on disease modification and symptom relief. Corticosteroids reserved for acute flares only.
Stage II: Full menu appropriate—PRP (multi-injection), hyaluronic acid, prolotherapy, BMAC, corticosteroids for flares. Selection based on patient history and goals.
Stage III: PRP, hyaluronic acid, BMAC, corticosteroids for palliation. Surgical consultation if multiple modalities fail. Realistic expectations are essential.
Stage IV: Surgical consultation is the primary recommendation. Injections may play a palliative role for non-surgical candidates.
Corticosteroids and hyaluronic acid have the most RCT evidence. PRP has growing Level 1 evidence with protocol-dependent outcomes. Prolotherapy has RCT support but fewer studies. BMAC represents early-stage evidence.
When to Seek a Surgical Consultation: Understanding the Non-Surgical Window
Approximately 22–33% of patients convert from nonsurgical to surgical management, with most conversions occurring within the first year of conservative treatment.
Clear surgical thresholds include Stage IV disease, failure of multiple injection modalities across Stages II–III, and progressive functional decline despite optimized non-surgical care.
The 2026 five-year RCT data showing that total joint arthroplasty did not demonstrate superior patient-reported outcomes compared to trapeziectomy reinforces that surgical options also involve meaningful trade-offs. Patients considering their options may benefit from a knee replacement second opinion approach—seeking an independent assessment before committing to any surgical intervention.
Exhausting non-surgical options is not “delaying the inevitable”—it is appropriate medical management. Many patients achieve long-term relief without surgery.
Conclusion: Matching the Right Injection to the Right Stage Changes Outcomes
The Eaton-Littler classification is not merely a radiographic curiosity—it is a practical decision tool that should guide injection selection for every CMC arthritis patient.
The PRP nuance bears repeating: the 2025 Stockholm RCT found a single PRP injection no better than placebo, but multi-injection protocols show significantly better outcomes at 12 months. Protocol matters as much as the agent itself.
The absence of formal EULAR or ACR endorsement for intra-articular injections in TMC osteoarthritis does not mean injections are ineffective—it means patients and clinicians must navigate the evidence together, with a structured framework as their guide.
From corticosteroids and hyaluronic acid to PRP, prolotherapy, BMAC, and emerging collagen scaffolds, the options for non-surgical CMC joint management have never been broader. Knowing one’s Eaton stage, asking about imaging guidance, and understanding the evidence behind each injection type positions patients to make informed decisions and achieve better outcomes.
Ready to Explore Stage-Appropriate Injection Options for Thumb Arthritis?
Patients diagnosed with thumb CMC arthritis—or those suspecting they may have it—benefit from understanding their Eaton stage and which injection options are appropriate for their degree of joint involvement.
Unicorn Bioscience offers the full spectrum of regenerative injection options—PRP, BMAC, hyaluronic acid, and more—with precision imaging guidance at every procedure. The practice serves patients across Texas (Austin, Dallas, El Paso, Fort Worth, Houston, San Antonio), Florida (Boca Raton), and New York (Manhattan), with virtual consultation options available.
To discuss specific staging, symptoms, and injection candidacy with a qualified provider, contact Unicorn Bioscience at (737) 347-0446 or visit unicornbioscience.com. Personalized treatment planning based on individual patient factors—rather than a one-size-fits-all corticosteroid default—defines the approach.
Schedule Your Consultation Today!
